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Abstract 
 
The fused quinazolinone derivative, RX-207, is chemically and functionally related to small 
molecule inhibitors of protein binding to glycosaminoglycans (SMIGs). Composed of a planar 
aromatic amine scaffold, it inhibits protein binding to glycosaminoglycans (GAGs).  RX-207 
reduced neutrophil migration in thioglycollate induced peritonitis (37%), inhibited 
carrageenan induced paw edema (32%) and cerulein induced pancreatitis (28%) and 
increased animal survival in the mouse model of cecal ligation and puncture (CLP) induced 
sepsis (60%). The mechanism of RX-207 action, analyzed by UV spectroscopy, confirmed 
that which was elucidated for chemically related anti-inflammatory SMIGs. RX-207 binding 
to cell surface GAGs can account for the inhibition of neutrophil recruitment via the micro-
vasculature and as a consequence the reduction of neutrophil mediated tissue damage in 
the animal models of inflammation and improved survival of mice in CLP induced sepsis.  
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Introduction 
 
Contemporary medicine treats inflammatory disorders with a variety of medications. 
Corticosteroids are the most effective drugs for acute inflammation and are efficacious, at a 
low dose, in treating chronic inflammation [1]. Inflammatory disorders that are refractory to 
treatment, such as acute pancreatitis and sepsis, can be fatal. The absence of effective 
treatment of sepsis is not for want of effort, or resource. There are more than four hundred 
reports of preclinical studies of the pro-inflammatory cytokine, tumor necrosis factor alfa 
(TNF-), alone and more than one hundred clinical trials have been carried out on anti-
inflammatory drug candidates [2]. Many and various explanations have been given for the 
clinical failure of drugs in treating sepsis [3]. One, for example, is the difficulty in defining 
the disease [4], another is the temporal heterogeneity in sepsis development and a third 
explanation is the biological heterogeneity resulting from patient age, comorbidities and 
pathogens [5]. What is true for sepsis and inflammatory disorders in general, is that 
inflammation is the net result of the activities of multiple biochemical pathways. 
Modulation of any one pathway, therefore, is unlikely to influence the course of the illness 
in a significant way. Profound changes in the endothelium of venules, as a result of sepsis, 
cause vasodilation, loss of barrier function and widespread tissue edema [6]. Neutrophils, 
the principal effectors of endothelial damage in sepsis [7], are potential targets for anti-
inflammatory drugs. Therapeutic modulation of inflammatory neutrophils potentially could 
reduce tissue edema and prevent the damage caused by the reactive oxygen species, 
proteases and pro-inflammatory cytokines that they secrete [8]. Anti-inflammatory small 
molecule inhibitors of protein binding to glycosaminoglycans (SMIGs) have been described 
[9] and their mechanism of action in experimental models of inflammation elucidated [10]. 
The current manuscript describes the anti-inflammatory activity of a novel SMIG, 
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demonstrates its efficacy in experimental sepsis and delineates and confirms the 
mechanism of action that can account for the inhibition of inflammatory neutrophil 
adhesion and activity in the disease. 
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Materials and Methods 
 
Materials  
Quinazolinone derivatives were purchased from, or custom-synthesized by Life Chemicals 
Ltd. (Kiev, Ukraine) and ChemDiv (San Diego, CA); heparin sodium salt (porcine intestinal 
mucosa, Cat# 51551), chondroitin 6-sulfate sodium salt (shark cartilage, Cat# C4384), 
carrageenan (Cat# C-3889 ), cerulein (Cat# C-9026 ), Tween 80, DMSO, thioglycollate (Cat# 
T-0632) were purchased from Sigma-Aldrich Corporation, (St Louis, MO); Türk’s reagent was 
purchased from (Merck, Germany, Cat# 109277); Balb/c mice were provided by Velaz 
(Prague, Czech Republic); the solubility of RX-207 is 20 mg/mL in 50 mM citric acid.  
 
Methods 
Thioglycollate-induced peritonitis1 
BALB/c mice (6 weeks old, 19 g in weight, 12 mice/group) received p.o. inhibitor 
compound in 0.1 mL methylcellulose 1 hour before administration of thioglycollate. Control 
groups received vehicle only. Mice were injected intraperitoneally with 1 mL of 3% 
thioglycollate broth [11]. Mice were sacrificed after 3 hours, and the peritoneal cavities 
were lavaged with 5 mL of ice-cold saline containing 2 mM EDTA to prevent clotting. After 
red blood cell lysis, leukocytes were counted in a hemocytometer. Neutrophils were 
counted after staining with Türk’s reagent. Data was expressed as mean ± SEM, and 
statistical analysis was performed by Student t test.  
Quinazolinone (RX-207) formulation 
RX 207 was dissolved in a mixture of propylenglycol (41%, Fluka, Biochemika), PEG400 (9%, 
Fluka, Biochemika) and water (pharmaceutical grade). 
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Carrageenan-induced paw edema1 
Acute edema was induced in the right hind paw of BALB/c mice (8 weeks old, 21 g in 
weight, 12 mice/group) by injecting 0.05 mL of freshly prepared solution of 1% carrageenan 
after 60 min of test compound administration [12]. The left paw received 0.05 mL of saline, 
which served as a control. Carrageenan was injected under the plantar region of right hind 
paw and the paw thickness was measured at  4 hours after carrageenan challenge using a 
Mitutoyo engineer’s micrometer expressed as the difference between right and left pad as 
mean ± SEM. Results were evaluated by Student’s t test. 
Acute pancreatitis1 
Acute pancreatitis was induced in Balb/c mice (8 weeks old, 22 g in weight, 10-11 mice per 
group) by injecting cerulein (50 g/kg, i.p., X7; [13]). The cerulein model of acute 
pancreatitis is a commonly used pharmaceutical industry model. Test compounds were 
administered i.m or i.v. 1h prior to first cerulein injection. One hour after the last cerulein 
injection blood samples were taken. Serum amylase was analysed by standard methods 
[14]. Amylase data were calculated as units per volume and expressed as mean ± SEM. 
Results were evaluated by Student’s t test.  
Cecal ligation and puncture (CLP, a model of sepsis)1 
CLP was performed in the control and experimental Balb/c mice (8 weeks old, 22 g in 
weight, 9-10 mice per group) as described by Fink [15]. The experimental mice were given 
RX-207 or RX-205 (20 mg/kg, 0.1ml, i.m.), 24 hours before surgery and once per day for the 
duration of the study. Survival data were evaluated by Log-rank (Mantel-Cox) test. 
UV absorption spectroscopy 
UV absorption spectra were recorded on a JASCO J-715 spectropolarimeter at 25 ± 0.2 °C. 
Temperature control was provided by a Peltier thermostat equipped with magnetic stirring. 
Each spectrum represents the average of two scans obtained by collecting data at a scan 
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speed of 200 nm/min. 2.3 mM stock solution of RX-207 was prepared using ultra-pure water 
and a small volume of ethanol. 25 or 30 L stock solution of the ligand was added to 1.8 mL 
ultra-pure water in a rectangular quartz cell of 1 cm optical path length (Hellma, USA). Drug 
samples obtained by this way were subsequently titrated by small aliquots of concentrated 
aqueous solution of heparin and chondroitin 6-sulfate. Due to their poly-disperse nature, 
glycosaminoglycan (GAG) concentrations were expressed using the molecular weight of the 
average repeating disaccharide units: 665 and 503 g/mol for heparin and chondroitin 6-
sulfate, respectively. Absorption curves of drug-GAG mixtures were corrected by subtracting 
the spectra of blank water solution. 
 
1 The animal experiments were reviewed and approved by the Ethical Committee for animal 
experimentation of the Institute of Animal Physiology, approved by the State Veterinary and 
Food Administration of the Slovak Republic and were performed in accordance with Slovak 
legislation based on EC Directive 86/609/EEC on the protection of animals used for 
experimental and other scientific purposes. 
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Results 
 
 
RX-207 and RX-205, inhibitors of neutrophil migration 
 
An in vitro screen of SMIGs identified the anti-inflammatory quinazolinone, RX-211, with IC50 
values in the low micro-molar range and broad activity against inflammatory chemokines 
and cytokines [9]. Derivatives of related compounds, the fused quinazolinones, RX-207 
(azepino[2,1-b]quinazoline-6,7,8,9,10,12-hexahydro-12-oxo-N-(1-methylethyl-piperidinyl-4)-
3-carboxamide, Figure 1A and RX-205 (pyrrolo[2,1-b]quinazoline-1,2,3,9-tetrahydro-9-oxo-
N-(1-methyl-piperidinyl-4)-6-carboxamide), Figure 1B, were predicted to have anti-
inflammatory activity in animal models of inflammation.  
Thioglycollate induced peritonitis that results in a massive neutrophil infiltrate into the 
peritoneum [16], is a frequently used animal model to study acute inflammation [17]. Oral 
administration of RX-205 and RX-207 (50 mg/kg) inhibited neutrophil migration into the 
peritoneal cavity by 38% and 37%, respectively (Figure 2).   
 
RX-207 anti-inflammatory activity 
Carrageenan-induced inflammation is characterized by the migration of leukocytes, mainly 
neutrophils, to the site of inflammation [18]. Carrageenan-induced edema of the mouse 
paw is a model of acute local inflammation to evaluate the anti-inflammatory activity of 
investigational compounds [12]. Intra-muscular (i.m.) injection of RX-207 (1 mg/kg, 0.1ml) 
inhibited carrageenan-induced paw edema in mice (32%), as measured by a reduction in 
paw thickness (Figure 3). RX-205 (25 mg/kg), administered i.v., reduced paw thickness by 
24% (p<0.001, data not shown). 
Supra-physiologic doses of cerulein cause acute pancreatitis in mice reproducing 
morphological and biochemical features of the human disease [13]. Models of cerulein 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
9 
 
induced pancreatitis, characterized by increased serum amylase activity, have been used to 
study acute pancreatitis and to test potential drugs [19]. RX-207 (25 mg/kg, 0.1ml), 
administered i.m., reduced serum levels of amylase by 28% (Figure 4). RX-205 (20 mg/kg), 
administered i.v., reduced amylase activity by 34% (p<0.01, data not shown). 
 
RX-207 and RX-205 therapeutic activity  
Cecal Ligation and Puncture (CLP) causes poly-microbial sepsis, a procedure used for 
modeling sepsis in vivo [15]. CLP in the mouse model of sepsis resulted in 70% mortality 
(Figure 5). Treatment with RX-207 and RX-205 (20 mg/kg each, 0.1ml, i.m), 24 hours before 
surgery and once per day for the duration of the study, increased survival rate by 60% and 
50%, respectively. Body weight decreased to the same extent (22-23% of starting values) in 
both experimental and control groups (Figure 6). 
 
Mechanism of RX-207 action  
 
The related quinazolinone derivatives, RX-207 and RX-205 (30 M) inhibited binding of the 
pro-inflammatory chemokine, MCP-3, to heparin, a highly sulfated form of the cell surface 
GAG, heparan sulfate (data not shown). The inhibition of MCP-3, the only one of ten heparin 
binding chemokines, cytokines and selectins tested, was an indication of target specificity. 
RX-207 and RX-205 (30 M) inhibited binding of the pro-inflammatory chemokine, IP-10, to 
the extracellular matrix GAG, chondroitin sulfate (CS, data not shown), extending the range 
of GAGs targeted by SMIGs. Spectroscopic analysis was carried out to elucidate the 
interaction of RX-207 with the GAGs. UV absorption spectra of RX-2007 were determined in 
the absence and presence of CS and heparin. The spectrum, recorded in water, exhibited 
multiple peaks at a wavelength greater than 200 nm, the most intense one (max 35,000 M-
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1 cm-1) centered around 235 nm (Figure 7). Heparin induced a dose dependent reduction in 
the molar absorption coefficient (max), the experimental proof of quinazolinone binding to 
the GAG. 
At the initial phase of the titration, heparin produced a moderate (12%) but abrupt 
reduction in the intensity of the main UV peak (Figure 8). Further addition of heparin 
induced opposite, but slower changes, restoring the molar absorption coefficient close to its 
original value (Figure 8). Compared with heparin, interaction of RX-207 with CS resulted in a 
very small decrease (3%) of the max value (Figure 8). A small concentration of NaCl 
promptly restored the original absorption intensities of RX-207 in the presence of heparin 
and CS (Figure 9). No circular dichroism signals were induced either by heparin or CS (data 
not shown). 
 
Discussion 
 
Activated neutrophils have an extended half-life and an altered biochemical profile [20]. 
They remain in the blood stream, express inflammatory signals that alter blood vessel 
permeability [21] and release reactive oxygen species, proteolytic enzymes and pro-
inflammatory cytokines [8]. Neutrophil apoptosis and phagocytosis of the apoptotic cells 
resolve the inflammatory response [22]. Inordinate neutrophil activity impairs innate anti-
oxidant and anti-protease activity and stimulates indiscriminate proteolysis, the hallmark of 
inflammatory disorders [23]. Enteral administration of the quinazolinone related derviatives, 
RX-207 and RX-205, inhibited thioglycollate induced neutrophil migration (Figure 2), 
parenteral administration of RX-207 inhibited carrageenan induced paw edema (Figure 3) 
and intramuscular injection of RX-207 inhibited a neutrophil mediated increase in serum 
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amylase in cerulein induced acute pancreatitis (Figure 4). RX-207 appeared to be 
responsible for inhibiting neutrophil recruitment and consequent inflammation in the three 
animal models of disease. 
Intramuscular injection of RX-207 and RX-205 significantly reduced mouse mortality, 60% 
and 50% respectively, in CLP-induced sepsis (Figure 5). The weights of the experimental and 
the control animals leveled off at 80% of starting values (Figure 6) and a dose of 1,500 
mg/kg (RX-205, toxicity study, not shown) did not produce any adverse clinical symptoms. 
The efficacy in CLP-induced sepsis, a poly-microbial sepsis that reflects clinical reality more 
than any other animal model of systemic inflammation [24], is predictive of therapeutic 
potential.  
RX-207 inhibited the selective binding of MCP-3 to heparin and IP-10 binding to CS. 
Spectroscopic analysis of RX-207 was carried out to study its interaction with the respective 
GAGs (Figure 7). Heparin induced dose-dependent hypochromism [25], a reduction in max 
that is experimental proof of RX-207 binding to the GAG. UV hypochromism is due to 
electronic interactions between the planar quinazolinone moieties of RX-207 molecules 
(dimers or oligomers) arranged proximally along the heparin chain. The largest reduction in 
the max of RX-207 was observed around RX-207:disaccharide molar ratio of 2:1 (Figures 7 
and 8), suggesting the association of two RX-207 molecules per disaccharide unit of the 
heparin chain. Restoration of the molar absorption coefficient to its original value by the 
further addition of heparin (Figure 8) might be indicative of a shift in the stoichiometry, back 
from 2:1 to 1:1. Due to the molar excess of heparin binding sites, the monomeric association 
of RX-207 became more prevalent, canceling the hypochromism. It seems that the structure 
of the disaccharide unit of CS (lower charge density vs. heparin, Figure 9) did not favor the 
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dimeric binding of RX-207. A low concentration of NaCl was observed to promptly restore 
the original absorption intensities of RX-207 in the presence of either heparin or CS, 
suggesting that Na+ ions effectively disrupt the Coulombic interactions between the acidic 
groups of GAGs and the protonated piperidine nitrogen of RX-207 (Figure 1). The 
dissociation of the RX-207-GAG complexes provides a rationale for the inactivity of RX-207 
in inhibiting protein binding to heparin in the presence of salt.  
RX207 inhibits pro-inflammatory MCP-3 binding to heparin (current manuscript) and anti-
inflammatory SMIGs inhibit binding of the pro-inflammatory cytokines, IL-6 and IL-8 [9]. 
Exactly how the anti-inflammatory SMIGs influence cytokine expression has not yet been 
investigated. This is a question that should be addressed given that the anti-inflammatory 
cytokine, IL-10, protects mice from bacterial sepsis [26] and the anti-inflammatory IL-13 
prevents lethality in a mouse model of neonatal sepsis in humans, neonatal endotoxin shock 
[27]. 
The endothelial lumen of the micro-vasculature is decorated with glycocalyx, an 
extracellular matrix that mediates vascular barrier function, leukocyte adhesion and anti-
oxidant defense [28]. Leukocyte adhesion molecules, embedded in the glycocalyx, are 
shielded from circulating leukocytes. Sepsis causes glycocalyx shedding, exposes lymphocyte 
adhesion molecules and liberates endogenous damage associated molecular patterns 
(DAMPs, [29]), including heparan sulfates, themselves inducers of sepsis [30]. Neutrophils, 
adhering to the glycocalyx and extravasating into proximal tissue, release heparin binding 
protein (HBP, [31]) that binds to cell surface proteoglycans and induces vascular leakage 
[32]. Spectral analysis showed that RX-207 bound directly to the GAG, heparin (Figure 7), 
confirmation of the mechanism of action elucidated for chemically distinct, but functionally 
related anti-inflammatory SMIGs [10]. Glycocalyx of the inflamed micro-vasculature 
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provides the pathologic context for anti-inflammatory SMIG activity. SMIGs have the 
potential to prevent inflammatory neutrophils adhering to microvasculature and 
extravasating into proximal tissue, inhibit heparin binding proteins that cause vascular 
leakage and neutralize sepsis inducing heparan sulfates. 
At the time of submitting this manuscript no small molecule therapy for sepsis had been 
approved [33]. The efficacy of SMIGs in a severe experimental model of sepsis (current 
report), colitis and experimental autoimmune encephalomyelitis [10], underscores the 
potential of the glycocalyx in general and GAGs in particular, as biological targets for the 
treatment of deleterious inflammation. RX-207 and RX-205 are chemically related to 
therapeutic quinazolinones, a number of which have anti-inflammatory activity [34], [35], 
[36]. Anti-inflammatory SMIGs, with defined biological targets and an elucidated mechanism 
of action, are potential therapeutics for diverse, but pathogenically related inflammatory 
disorders.  
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    Fig. 1 (A) RX-207, (B) RX-205 
 
 
 
            
 
          Fig. 2 Inhibition of neutrophil migration by RX-205 and RX-207 (50 mg/kg,  
         per os) in a mouse model of thioglycollate induced peritonitis (** p < 0.01) 
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Fig. 3 Anti-inflammatory activity of RX-207 in a mouse model of carrageenan-induced 
edema. RX-207 (1 mg/kg) was administered i.m. one hour before injecting carrageenan. Paw 
edema was determined 4 hours after administering carrageenan. The Y axis represents 
difference in paw thickness between carrageenan treated and non-treated paws 
(***p<0.001) 
 
 
 
 
             
     
Fig. 4 Therapeutic activity of RX-207 in a mouse model of acute pancreatitis. RX-207  
(25 mg/kg) was administered i.m. one hour before injecting cerulein. Serum amylase  
was analyzed one hour after the last injection of cerulein (*p<0.05)  
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                   Fig. 5 Therapeutic activity (survival rate) of RX-205 (20 mg/kg,  
                   i.m., *p=0.0123) and RX-207 (20 mg/kg, i.m., *p=0.0233)  
                   in the mouse model  of CLP-induced sepsis. *Log-rank (Mantel- 
                   Cox) test for CLP survival 
 
 
 
 
                       
                       
            Fig. 6 Change in body weight of mice treated with RX-205 (20 mg/kg,  
            i.m.) and RX-207 (20 mg/kg, i.m.) in the mouse model of CLP-induced 
            sepsis  
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                           Fig. 7 Effect of heparin on the UV absorption spectrum of RX-207    
                           measured in aqueous solution  
 
 
                                              
                        Fig. 8 Effect of addition of heparin and CS on the max value of RX-207 
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                         Fig. 9 Effect of sodium chloride on the max of RX-207 bound to  
                         heparin and CS. Inset shows the average repeating disaccharide  
                         unit of CS and heparin 
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